# THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult your licensed securities dealer, other licensed corporation, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in Hongkong Chinese Limited, you should at once hand this circular and the accompanying form of proxy to the purchaser or transferee or to the bank, licensed securities dealer or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



(Incorporated in Bermuda with limited liability)
(Stock Code: 655)

# PROPOSED GRANT OF GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES, PROPOSED RE-ELECTION OF RETIRING DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING

A notice convening the annual general meeting of Hongkong Chinese Limited to be held at Harcourt Room, Lower Lobby, Conrad Hong Kong, Pacific Place, 88 Queensway, Hong Kong on Tuesday, 8 June 2021 at 10:15 a.m. or any adjourned meeting thereof to approve matters referred to in this circular is set out on pages 11 to 15 of this circular.

Whether or not you are able or intend to attend such meeting, please complete and return the accompanying form of proxy in accordance with the instructions printed thereon as soon as possible and in any event not less than 48 hours before the time appointed for holding such meeting, or any adjourned meeting thereof, to the principal place of business of Hongkong Chinese Limited at 40th Floor, Tower Two, Lippo Centre, 89 Queensway, Hong Kong. Completion and return of the form of proxy will not preclude you from attending and voting in person at the annual general meeting or any adjourned meeting thereof should you so wish and in such event, the instrument appointing the proxy shall be deemed to be revoked.

Your attention is drawn to the section headed "PRECAUTIONARY MEASURES FOR THE AGM" at the end of this circular for measures to try to prevent and control the spread of the COVID-19 coronavirus pandemic at the meeting.

# **CONTENTS**

	Page
Definitions	1
Letter from the Board	
Introduction	3
General mandates to issue and repurchase Shares	4
Explanatory statement	4
Re-election of retiring Directors	7
Annual General Meeting	9
Voting by poll at general meetings	10
Recommendation	10
Notice of Annual General Meeting	11
Precautionary measures for the AGM	16

# **DEFINITIONS**

In this circular, the following terms and expressions shall have the following meanings unless the context otherwise requires:

"AGM" the annual general meeting of the Company to be held at

Harcourt Room, Lower Lobby, Conrad Hong Kong, Pacific Place, 88 Queensway, Hong Kong on Tuesday, 8 June 2021 at 10:15 a.m., notice of which is set out on pages 11 to 15 of

this circular, or any adjourned meeting thereof;

"Board" board of the Directors;

"Bye-law(s)" bye-law(s) of the Company;

"close associates" has the meaning ascribed to it in rule 1.01 of the Listing

Rules;

"Companies Act" Companies Act 1981 of Bermuda;

"Company" Hongkong Chinese Limited (香港華人有限公司\*),

a company incorporated in Bermuda with limited liability, the Shares of which are listed on the Stock Exchange;

"core connected persons" has the meaning ascribed to it in rule 1.01 of the Listing

Rules;

"Director(s)" director(s) of the Company;

"DNP" the Directors' Nomination Policy of the Company;

"Dr Riady" Dr Stephen Riady;

"HK\$" Hong Kong dollar, the lawful currency of Hong Kong;

"Hong Kong" the Hong Kong Special Administrative Region of the

People's Republic of China;

"Latest Practicable Date" 23 April 2021, being the latest practicable date prior to the

printing of this circular for ascertaining certain

information contained therein;

"LCR" Lippo China Resources Limited, a fellow subsidiary of the

Company listed on the Stock Exchange;

"Lippo" Lippo Limited, an intermediate holding company of the

Company listed on the Stock Exchange;

<sup>\*</sup> For identification purpose only

# **DEFINITIONS**

"Listing Rules" the Rules Governing the Listing of Securities on the Stock

Exchange;

"Mr Neo" Mr Edwin Neo;

"Report of the Directors" the Report of the Directors in the 2020 Annual Report of

the Company;

"Retiring Directors" Dr Riady and Mr Neo;

"SFO" the Securities and Futures Ordinance (Chapter 571 of the

Laws of Hong Kong);

"SGX-ST" Singapore Exchange Securities Trading Limited;

"Share(s)" ordinary share(s) of HK\$1.00 each in the share capital of

the Company;

"Shareholder(s)" holder(s) of the Share(s);

"Stock Exchange" The Stock Exchange of Hong Kong Limited;

"Takeovers Code" the Code on Takeovers and Mergers;

"Three Committees" the Audit Committee, the Remuneration Committee and the

Nomination Committee; and

"%" per cent.



# HONGKONG CHINESE LIMITED 香港華人有限公司\*

(Incorporated in Bermuda with limited liability)
(Stock Code: 655)

Executive Directors:

Dr Stephen Riady (Chairman)

Mr John Luen Wai Lee, BBS, JP (Chief Executive Officer)

Non-executive Director:

Mr Leon Nim Leung Chan

Independent non-executive Directors:

Mr Victor Ha Kuk Yung

Mr King Fai Tsui

Mr Edwin Neo

Registered Office:

Clarendon House

Church Street

Hamilton HM 11

Bermuda

Principal Place of Business:

40th Floor

Tower Two

Lippo Centre

89 Queensway

Hong Kong

29 April 2021

To the Shareholders

Dear Sir or Madam.

# PROPOSED GRANT OF GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES, PROPOSED RE-ELECTION OF RETIRING DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING

# INTRODUCTION

The purpose of this circular is to provide Shareholders with all the information reasonably necessary to enable them to make an informed decision on whether to vote for or against the resolutions mentioned herein which will be dealt with at the AGM to be held at Harcourt Room, Lower Lobby, Conrad Hong Kong, Pacific Place, 88 Queensway, Hong Kong on Tuesday, 8 June 2021 at 10:15 a.m., and to convene the AGM, notice of which is set out on pages 11 to 15 of this circular. This circular contains information concerning the proposed general mandates to issue and repurchase Shares and the proposed re-election of retiring Directors which is required to be sent to Shareholders under the Listing Rules.

<sup>\*</sup> For identification purpose only

#### GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES

As the previous general mandates to issue and repurchase Shares granted to the Directors at the annual general meeting of the Company held on 8 September 2020 will expire on conclusion of the AGM, ordinary resolutions relating to renewal of general mandates will be proposed at the AGM:

- (i) authorising the Directors to allot, issue and otherwise deal with additional Shares (and securities convertible into Shares) not exceeding 20% of the total number of issued Shares as at the date of passing of the resolution, as set out in Resolution No. 5A of the notice of AGM;
- (ii) authorising the Directors to repurchase Shares not exceeding 10% of the total number of issued Shares as at the date of passing of the resolution, as set out in Resolution No. 5B of the notice of AGM; and
- (iii) authorising the addition to the mandate to issue new Shares (referred to at (i) above) those Shares repurchased by the Company pursuant to the repurchase mandate (referred to at (ii) above), as set out in Resolution No. 5C of the notice of AGM.

In accordance with the Listing Rules, and in particular the rules regulating repurchase of securities on the Stock Exchange, the Company is required to send to Shareholders an explanatory statement containing all the information reasonably necessary to enable Shareholders to make an informed decision on whether to vote for or against the resolution to approve the repurchase by the Company of its Shares. This explanatory statement is set out below.

#### **EXPLANATORY STATEMENT**

At the AGM, an ordinary resolution will be proposed which, if passed, will give the Directors a general and unconditional mandate to exercise all powers of the Company to repurchase issued Shares subject to the criteria set out in this circular. In particular, Shareholders should note that the maximum number of Shares that may be repurchased pursuant to the mandate must not exceed such number of Shares representing 10% of the total number of issued Shares as at the date of passing of the relevant resolution.

# 1. Share capital

As at the Latest Practicable Date, there were 1,998,280,097 Shares in issue. On the basis of this figure and assuming no further Shares of the Company are issued or repurchased prior to the AGM, not more than 399,656,019 Shares (representing approximately 20% of the total number of Shares in issue) may be issued by the Company, and not more than 199,828,009 Shares (representing approximately 10% of the total number of Shares in issue) may be repurchased on the Stock Exchange during the period from the passing of the resolutions at the AGM until whichever is the earliest of: (i) the conclusion of the next annual general meeting of the Company; (ii) the expiration of the period within which the next annual general meeting of the Company is required by any applicable law or the Bye-laws of the Company to be held; or (iii) the revocation or variation of the authority given under the resolutions by ordinary resolutions of the Shareholders in general meeting.

# 2. Reasons for repurchases

While it is not possible to anticipate in advance any specific circumstances in which the Directors might think it appropriate to repurchase Shares, the Directors believe that an ability to do so would give the Company additional flexibility that would be beneficial to the Company. The repurchases may, depending on market conditions and funding arrangements of the Company at the time, lead to an enhancement of the net asset value per Share and/or earnings per Share. Shareholders can be assured that the Directors would only make such repurchases in circumstances where they consider them to be in the interests and for the benefit of the Company.

# 3. Funding of repurchase

The Company is empowered by its Memorandum of Association and Bye-laws to repurchase its Shares. Repurchases of Shares must be funded out of funds legally available for the purpose in accordance with the Bye-laws and the laws of Bermuda. The Companies Act provides that the amount of capital paid in connection with a share repurchase may only be paid out of the capital paid up on the relevant shares, or the funds of the Company which would otherwise be available for dividend or distribution or the proceeds of a fresh issue of shares made for the purpose. The amount of premium payable on repurchase may only be paid out of either the funds of the Company which would otherwise be available for dividend or distribution or out of the share premium account of the Company. The Companies Act further provides that such repurchase may only be made if on the effective date of the repurchase, there are no reasonable grounds for believing that the Company is, and after the repurchase would be, unable to pay its debts as they fall due.

On the basis of the consolidated financial position of the Company as at 31 December 2020 (being the date to which the latest published audited financial statements of the Company have been made up) and in particular the working capital position of the Company at that time and the number of Shares now in issue, the Directors consider that there might be a material adverse impact on the working capital or gearing position of the Company in the event that the proposed repurchases were to be carried out in full at any time during the proposed repurchase period.

However, no repurchases would be made in circumstances that would have a material adverse impact on the working capital or gearing position of the Company (as compared with the financial position as at 31 December 2020) unless the Directors believe that such repurchases are in the interests and for the benefit of the Company.

# 4. Share prices

During each of the twelve months immediately preceding and up to and including the Latest Practicable Date, the highest and lowest traded prices for Shares on the Stock Exchange were as follows:

	Highest	Lowest
	HK\$	HK\$
2020		
April	0.86	0.60
May	0.84	0.66
June	0.78	0.66
July	0.75	0.65
August	0.75	0.64
September	0.75	0.63
October	0.68	0.63
November	0.74	0.63
December	0.68	0.64
2021		
January	0.71	0.63
February	0.72	0.64
March	0.72	0.66
April (up to and including the Latest Practicable Date)	0.70	0.65

### 5. Disclosure of Interests

The Directors have undertaken to the Stock Exchange that they will exercise the power of the Company to make repurchases pursuant to the proposed resolution in accordance with the Listing Rules and all applicable laws of Bermuda, the jurisdiction in which the Company was incorporated, and in accordance with the regulations set out in the Memorandum of Association and Bye-laws of the Company.

If, as a result of a share repurchase by the Company, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition for the purpose of the Takeovers Code. As a result, a Shareholder or group of Shareholders acting in concert, could obtain or consolidate control of the Company and thereby become obliged to make a mandatory offer in accordance with Rules 26 and 32 of the Takeovers Code.

As at the Latest Practicable Date, to the best of the knowledge and belief of the Company, Lippo was beneficially interested in 1,477,715,492 Shares, representing approximately 73.95% of the total number of issued Shares. In the event that the Directors exercise in full the power to repurchase Shares which is proposed to be granted pursuant to the relevant ordinary resolution at the AGM, the shareholding interest of Lippo in the Company would be increased to approximately 82.17%. Such increase would not give rise to an obligation to make a mandatory offer under Rule 26 of the Takeovers Code. The Directors are not aware of any consequence which would arise

under the Takeovers Code as a result of any purchases by the Company of its Shares. The Directors have no intention to exercise the repurchase mandate to such extent as would cause the public float to fall below 25% or such other minimum percentage as prescribed by the Listing Rules from time to time.

None of the Directors nor, to the best of their knowledge and belief having made all reasonable enquiries, any of their respective close associates presently intend to sell any Shares to the Company or its subsidiaries in the event that the grant to the Directors of a repurchase mandate is approved by the Shareholders.

No core connected persons of the Company have notified the Company that they have any present intention to sell any Shares, or that they have undertaken not to sell any Shares held by them to the Company in the event that the Company is authorised to make purchases of Shares.

# 6. Share purchases made by the Company

The Company has not purchased any of its Shares (whether on the Stock Exchange or otherwise) in the six months preceding the Latest Practicable Date.

#### RE-ELECTION OF RETIRING DIRECTORS

In accordance with Bye-law 87 of the Bye-laws, the Retiring Directors will retire from office by rotation at the AGM and, being eligible, offer themselves for re-election.

The Nomination Committee of the Board has made recommendations to the Board after evaluation of the Retiring Directors in accordance with the DNP and in turn the Board recommends the Shareholders to approve the re-election of the Retiring Directors at the AGM.

Particulars of the Retiring Directors are as follows:

# **Dr Stephen Riady**

(former name: Stephen Tjondro Riady)

Dr Riady, aged 60, was appointed a Director of the Company on 1 September 1992 and the Chairman of the Board on 25 March 2011. He is also an executive director and the Chairman of the board of directors of each of Lippo and LCR. He was appointed the Executive President of each of the Company, Lippo and LCR with effect from 1 January 2015. He is a member of the Remuneration Committee and the Nomination Committee of the board of directors of each of the Company, Lippo and LCR. He also holds directorships in certain subsidiaries of the Company, Lippo and LCR. He is the Executive Chairman and the Group Chief Executive Officer of OUE Limited, a company listed on the Main Board of SGX-ST and a non-executive non-independent director of Healthway Medical Corporation Limited, a company listed on the Catalist Board of SGX-ST. He was a non-independent and non-executive director of OUE Lippo Healthcare Limited, a company listed on the Catalist Board of SGX-ST. He was a member of the board of commissioners of PT Lippo Karawaci Tbk, a company listed on the Indonesia Stock Exchange. Save as disclosed herein, he has not held any directorship in other public listed companies for the last three years.

Dr Riady is a graduate of the University of Southern California, the United States of America and holds a Master of Business Administration from Golden Gate University, the United States of America and an Honorary Degree of Doctor of Business Administration from Edinburgh Napier University, United Kingdom. He is one of the first Honorary University Fellows installed by the Hong Kong Baptist University in September 2006.

Dr Riady is a director of Lippo Capital Group Limited ("Lippo Capital Group"), Lippo Capital Holdings Company Limited ("Lippo Capital Holdings") and Lippo Capital Limited ("Lippo Capital") which, together with Lippo, have discloseable interests in the Company under Part XV of the SFO. He is the spouse of Madam Shincee Leonardi, a brother of Mr James Tjahaja Riady and a brother-in-law of Madam Aileen Hambali (the spouse of Mr James Tjahaja Riady). Their interests in the Company are disclosed in the section headed "Interests and short positions of shareholders discloseable under the SFO" in the Report of the Directors.

As at the Latest Practicable Date, Lippo Capital, through its subsidiary, Lippo, was indirectly interested in 1,477,715,492 Shares, representing approximately 73.95% of the issued Shares. Lippo Capital is a 60% owned subsidiary of Lippo Capital Holdings which in turn is a wholly-owned subsidiary of Lippo Capital Group. Dr Riady is the beneficial owner of one ordinary share in Lippo Capital Group, representing the entire issued share capital thereof. Accordingly, he was taken to be interested in 1,477,715,492 Shares, representing approximately 73.95% of the issued Shares pursuant to Part XV of the SFO. Further information about his interest in the Company was disclosed in the section headed "Directors' and chief executive's interests and short positions in shares, underlying shares and debentures of the Company and associated corporations" in the Report of the Directors.

Save as disclosed herein and in the Report of the Directors, as at the Latest Practicable Date, Dr Riady did not have any relationship with any Director, senior management and substantial or controlling shareholder of the Company.

Dr Riady entered into a letter agreement with the Company for his appointment as an Executive Director for a term of two years commencing from 1 January 2021, which is terminable by either party by giving three months' prior written notice or in accordance with the provisions of the Bye-laws. He is also subject to retirement by rotation and re-election at the Company's annual general meetings in accordance with the Bye-laws. Based on the above letter agreement, he is entitled to receive a Director's fee of HK\$246,000 per annum. He also entered into an employment agreement for his employment as Executive President of the Company with effect from 1 January 2015, which is terminable by either party by giving three months' prior written notice. Under the above employment agreement, he is entitled to receive a monthly salary of HK\$83,000, discretionary bonus and other fringe benefits. Discretionary bonus is not fixed in the employment agreement and is determined by the Remuneration Committee of the Board from time to time. For the nine months ended 31 December 2020, he received Director's fee, salaries, fringe benefits and pension contribution totalling approximately HK\$949,000 and a discretionary bonus of HK\$5,000,000 from the Company. His emoluments were determined by reference to his duties and responsibilities.

As at the Latest Practicable Date, Dr Riady did not have any matter that was required to be disclosed pursuant to paragraphs (h) to (v) of rule 13.51(2) of the Listing Rules or that needed to be brought to the attention of the Shareholders.

#### Mr Edwin Neo

Mr Neo, aged 71, was appointed an independent non-executive Director of the Company on 1 January 2018. He is also an independent non-executive director of Lippo and LCR. He is a member of the Three Committees of the board of directors of each of the Company, Lippo and LCR. He was an independent non-executive Director of the Company from 16 January 1995 to 10 March 1998. Save as disclosed herein, he has not held any directorship in other public listed companies for the last three years.

Mr Neo was admitted as a solicitor of the Supreme Court of Hong Kong in 1976 and of the Supreme Court of England and Wales in 1993. He is a practising lawyer and a notary public and is presently the senior partner of Hoosenally & Neo, Solicitors and Notaries. He holds a Bachelor of Laws degree with honours and Post-graduate Certificate in Laws from The University of Hong Kong.

Save as disclosed herein, as at the Latest Practicable Date, Mr Neo did not have any relationship with any Director, senior management and substantial or controlling shareholder of the Company.

As at the Latest Practicable Date, Mr Neo was not interested or deemed to be interested in any Shares or underlying Shares pursuant to Part XV of the SFO.

Mr Neo entered into a letter agreement with the Company for his appointment as an independent non-executive Director for a term of two years commencing from 1 January 2020, which is terminable by either party by giving three months' prior written notice or in accordance with the provisions of the Bye-laws. He is also subject to retirement by rotation and re-election at the Company's annual general meetings in accordance with the Bye-laws. Based on the above letter agreement, he is entitled to receive a director's fee of HK\$246,000 per annum which was determined by reference to the prevailing market rate for independent non-executive directors of listed companies in Hong Kong. He is also entitled to receive additional fees for serving as members of the Three Committees of the Board. For the nine months ended 31 December 2020, he received a director's fee of HK\$184,500 from the Company and additional fees totalling HK\$118,800 for serving as a member of the Three Committees of the Board.

As at the Latest Practicable Date, Mr Neo did not have any matter that was required to be disclosed pursuant to paragraphs (h) to (v) of rule 13.51(2) of the Listing Rules or that needed to be brought to the attention of the Shareholders.

# ANNUAL GENERAL MEETING

The notice convening the AGM is set out on pages 11 to 15 of this circular. A form of proxy for use at the AGM is enclosed. Whether or not you are able or intend to attend the AGM in person, please complete and return the accompanying form of proxy in accordance with the instructions printed thereon to the Company's principal place of business at 40th Floor, Tower Two, Lippo Centre, 89 Queensway, Hong Kong as soon as possible and in any event not less than 48 hours before the time appointed for the holding of the AGM or any adjourned meeting thereof. Completion and return of the form of proxy will not preclude you from attending and voting in person at the AGM or any adjourned meeting thereof should you so wish and in such event, the instrument appointing the proxy shall be deemed to be revoked.

# **VOTING BY POLL AT GENERAL MEETINGS**

Pursuant to the requirements under the Listing Rules, any votes of shareholders at a general meeting must be taken by poll except where the chairman of the meeting, in good faith and in compliance with the Listing Rules, decides to allow a resolution to be voted on by a show of hands. Therefore, the Chairman of the AGM will exercise his power under the Bye-laws to demand a poll for each resolution set out in the notice of AGM. The Company will appoint scrutineers to handle vote-taking procedures at the AGM. The results of the poll will be published on the websites of Hong Kong Exchanges and Clearing Limited at www.hkexnews.hk and the Company at www.hkchinese.com.hk as soon as possible after the conclusion of the AGM.

# RECOMMENDATION

The Directors consider that the proposed grant of general mandates to issue and repurchase Shares and the proposed re-election of retiring Directors are each in the best interests of the Company and the Shareholders, and accordingly recommend that the Shareholders vote in favour of the resolutions to be proposed at the AGM.

Yours faithfully,
By Order of the Board
HONGKONG CHINESE LIMITED
John Luen Wai Lee
Chief Executive Officer



# HONGKONG CHINESE LIMITED 香港華人有限公司\*

(Incorporated in Bermuda with limited liability)
(Stock Code: 655)

**NOTICE IS HEREBY GIVEN** that the Annual General Meeting of Hongkong Chinese Limited (the "Company") will be held at Harcourt Room, Lower Lobby, Conrad Hong Kong, Pacific Place, 88 Queensway, Hong Kong on Tuesday, 8 June 2021 at 10:15 a.m. for the following purposes:

- To receive and adopt the audited Consolidated Financial Statements of the Company and its subsidiaries, the Report of the Directors and the Independent Auditor's Report for the nine months ended 31 December 2020.
- 2. To consider and declare a final dividend for the nine months ended 31 December 2020.
- 3. A. To consider the re-election of Dr Stephen Riady as a Director of the Company;
  - B. To consider the re-election of Mr Edwin Neo as a Director of the Company; and
  - C. To authorise the Board of Directors of the Company to fix the Directors' remuneration.
- 4. To consider the re-appointment of Ernst & Young as the Auditor of the Company and to authorise the Board of Directors of the Company to fix its remuneration.
- 5. As special business, to consider and, if thought fit, pass the following resolutions as Ordinary Resolutions:

### A. "THAT:

(a) subject to paragraphs (c) and (d) of this resolution, the exercise by the Directors of the Company during the Relevant Period (as hereinafter defined) of all the powers of the Company to allot, issue and deal with additional shares in the capital of the Company and to make or grant offers, agreements and options (including warrants, bonds, debentures and other securities which carry rights to subscribe for or are convertible into shares of the Company), which would or might require the exercise of such powers be and is hereby generally and unconditionally approved;

<sup>\*</sup> For identification purpose only

- (b) the approval in paragraph (a) above shall be in addition to any other authorisation given to the Directors of the Company and shall authorise the Directors of the Company during the Relevant Period to make or grant offers, agreements and options (including warrants, bonds, debentures and other securities which carry rights to subscribe for or are convertible into shares of the Company), which might require the exercise of such powers after the end of the Relevant Period;
- the aggregate number of shares allotted or agreed conditionally or unconditionally to be allotted (whether pursuant to an option or otherwise) by the Directors of the Company pursuant to paragraphs (a) and (b) above, otherwise than pursuant to: (i) a Rights Issue (as hereinafter defined); (ii) the exercise of any options granted under any share option scheme of the Company; (iii) an issue of shares upon exercise of subscription rights pursuant to warrants (if any) issued by the Company; or (iv) any scrip dividend or similar arrangement providing for the allotment of shares in lieu of the whole or part of a dividend on shares of the Company, shall not exceed 20% of the total number of shares of the Company in issue as at the date of passing of this resolution, and the said approval shall be limited accordingly;
- (d) the Company may not issue securities convertible into shares for cash consideration unless the initial conversion price is not lower than the Benchmarked Price (as hereinafter defined) of the shares at the time of the relevant placing, and the Company may not issue warrants, options or similar rights to subscribe for (i) any new shares of the Company or (ii) any securities convertible into new shares of the Company, for cash consideration; and
- (e) for the purpose of this resolution:

"Benchmarked Price" means the higher of:

- (a) the closing price on the date of the relevant placing agreement or other agreement involving the proposed issue of securities under the general mandate in this resolution; and
- (b) the average closing price in the 5 trading days immediately prior to the earlier of:
  - the date of announcement of the placing or the proposed transaction or arrangement involving the proposed issue of securities under the general mandate in this resolution;
  - (ii) the date of the placing agreement or other agreement involving the proposed issue of securities under the general mandate in this resolution; and
  - (iii) the date on which the placing or subscription price is fixed;

"Relevant Period" means the period from the passing of this resolution until whichever is the earliest of:

- (i) the conclusion of the next annual general meeting of the Company;
- (ii) the expiration of the period within which the next annual general meeting of the Company is required by any applicable law or the Bye-laws of the Company to be held; or
- (iii) the revocation or variation of the authority given under this resolution by an ordinary resolution of the shareholders of the Company in general meeting; and

"Rights Issue" means an offer by way of rights to holders of shares whose names appear on the Register of Members of the Company on a fixed record date which enables those holders to subscribe shares in proportion to their then shareholdings (subject to such exclusions or other arrangements as the Directors of the Company may deem necessary or expedient in relation to fractional entitlements or having regard to any restrictions or obligations under the laws of, or the requirements of any recognised regulatory body or any stock exchange in, any territory applicable to the Company)."

# B. "**THAT**:

- (a) subject to paragraph (b) of this resolution, the exercise by the Directors of the Company during the Relevant Period (as hereinafter defined) of all the powers of the Company to repurchase issued shares of the Company on The Stock Exchange of Hong Kong Limited (the "Stock Exchange"), or on any other stock exchange on which the shares of the Company are or may be listed and recognised by the Securities and Futures Commission of Hong Kong and the Stock Exchange for this purpose, subject to and in accordance with all applicable laws and/or the requirements of the Rules Governing the Listing of Securities on the Stock Exchange or of any other stock exchange as amended from time to time, be and is hereby generally and unconditionally approved;
- (b) the aggregate number of shares of the Company which may be repurchased by the Company pursuant to the approval in paragraph (a) above during the Relevant Period shall not exceed 10% of the total number of shares of the Company in issue as at the date of passing of this resolution, and the said approval shall be limited accordingly; and

(c) for the purpose of this resolution:

"Relevant Period" means the period from the passing of this resolution until whichever is the earliest of:

- (i) the conclusion of the next annual general meeting of the Company;
- (ii) the expiration of the period within which the next annual general meeting of the Company is required by any applicable law or the Bye-laws of the Company to be held; or
- (iii) the revocation or variation of the authority given under this resolution by an ordinary resolution of the shareholders of the Company in general meeting."
- C. "THAT conditional on the passing of the resolutions set out in Resolutions No. 5A and 5B of the notice convening this meeting, the general mandate granted to the Directors of the Company and for the time being in force to exercise the powers of the Company to allot, issue and deal with additional shares of the Company and to make or grant offers, agreements and options which might require the exercise of such powers pursuant to the resolution set out in Resolution No. 5A of the notice convening this meeting be and is hereby extended by the addition to the aggregate number of shares of the Company which may be allotted or agreed conditionally or unconditionally to be allotted by the Directors of the Company pursuant to such general mandate of the aggregate number of shares of the Company repurchased by the Company under the authority granted pursuant to the resolution set out in Resolution No. 5B of the notice convening this meeting, provided that such extended number of shares shall not exceed 10% of the total number of shares of the Company in issue as at the date of passing of this resolution."

By Order of the Board
HONGKONG CHINESE LIMITED
Kelsch Wong
Secretary

29 April 2021

Registered Office: Clarendon House Church Street Hamilton HM 11 Bermuda

Principal Place of Business: 40th Floor Tower Two

Lippo Centre 89 Queensway

Hong Kong

#### Notes:

- 1. A member entitled to attend and vote at the above meeting is entitled to appoint another person as his proxy to attend and vote in his stead in accordance with the Bye-laws of the Company. A member who is the holder of two or more shares may appoint more than one proxy to represent him and vote on his behalf in accordance with the Bye-laws of the Company. A proxy need not be a member of the Company.
- 2. To be valid, a form of proxy, together with the power of attorney or other authority, if any, under which it is signed or a notarially certified copy of that power or authority, must be deposited at the principal place of business of the Company at 40th Floor, Tower Two, Lippo Centre, 89 Queensway, Hong Kong not less than 48 hours before the time appointed for the holding of the meeting or any adjourned meeting thereof. Completion and return of the form of proxy will not preclude a member from attending and voting in person at the meeting or any adjourned meeting thereof should he so wish and in such event, the instrument appointing the proxy shall be deemed to be revoked.
- 3. In light of the COVID-19 coronavirus pandemic, the Company will implement the precautionary measures at the meeting or any adjourned meeting thereof as set out in the Company's circular dated 29 April 2021. In the interest of the health and safety of members, members may consider to appoint the chairman of such meeting as their proxy to vote on the resolutions instead of attending such meeting in person.
- 4. The Register of Members of the Company will be closed during the following periods:
  - (i) from Thursday, 3 June 2021 to Tuesday, 8 June 2021 (both dates inclusive) during which period no transfer of shares will be registered, for the purpose of ascertaining shareholders' entitlement to attend and vote at the meeting. In order to be entitled to attend and vote at the meeting, all transfers of shares accompanied by the relevant share certificates and transfer forms must be lodged with Tricor Tengis Limited ("Tricor"), the Company's Branch Share Registrar in Hong Kong, at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong not later than 4:30 p.m. on Wednesday, 2 June 2021; and
  - (ii) from Tuesday, 15 June 2021 to Thursday, 17 June 2021 (both dates inclusive) during which period no transfer of shares will be registered, for the purpose of ascertaining shareholders' entitlement to the proposed final dividend. In order to qualify for the proposed final dividend scheduled to be paid on Friday, 25 June 2021, all transfers of shares accompanied by the relevant share certificates and transfer forms must be lodged with Tricor at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong not later than 4:30 p.m. on Friday, 11 June 2021.
- 5. At the meeting or any adjourned meeting thereof, the Chairman of such meeting will exercise his power under Bye-law 66(a) of the Bye-laws of the Company to put each of the above resolutions to the vote by way of a poll as required under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.
- 6. Should there be any discrepancies between the English and the Chinese versions of this notice, the English version shall prevail.

PRECAUTIONARY MEASURES FOR THE AGM

In view of the COVID-19 coronavirus pandemic and requirements for prevention and control of its spread, the Company will implement the following preventive measures at the AGM or any adjourned meeting thereof to protect attending Shareholders, Directors, staff and other attendees

from the risk of infection:

(i) Compulsory body temperature checks will be conducted on every Shareholder, proxy and

other attendee at the entrance of the AGM venue. Any attendee with a body temperature of over 37.3 degrees Celsius may be denied entry into the AGM venue or be required to leave

the AGM venue.

(ii) Each attendee may be required to complete and submit at the entrance of the AGM venue a

health declaration form giving his/her name and contact details and confirming that: he/she does not have any flu-like symptoms; he/she is not subject to any Hong Kong Government

prescribed quarantine; to his/her best of knowledge, he/she has not been in contact with any

person confirmed or suspected to have been infected with COVID-19 within 14 days immediately preceding the AGM; and he/she has not travelled, and to his/her best of

knowledge has not been in contact with any person who has travelled, outside Hong Kong

within 21 days immediately preceding the AGM. Any attendee who does not comply with

this requirement may be denied entry into the AGM venue or be required to leave the AGM

venue.

(iii) All attendees will be required to wear surgical face masks before they enter the AGM venue

and during their attendance at the AGM at all times, and to maintain a safe distance between seats. Any attendee who does not comply with this requirement may be denied entry into the

AGM venue or be required to leave the AGM venue.

(iv) No refreshments will be served and no corporate gifts will be distributed at the AGM.

The Company may change the precautionary measures as appropriate.

In the interest of the health and safety of all Shareholders, the Company reminds all Shareholders that physical attendance in person at the AGM is not necessary for the purpose of exercising their voting rights. The Shareholders may complete the form of proxy and appoint the Chairman of the AGM as their proxy to vote on the relevant resolutions at the AGM instead of attending the AGM in

person.

The form of proxy was despatched to the Shareholders together with this circular, and can otherwise be downloaded from the websites of the Company at www.hkchinese.com.hk or Hong

Kong Exchanges and Clearing Limited at www.hkexnews.hk.

If you have any questions relating to the AGM, please contact the Company's Branch Share

Registrar in Hong Kong, Tricor Tengis Limited, at the following:

Address: Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong

Email: is-enquiries@hk.tricorglobal.com

Telephone: (852) 2980 1333

Fax: (852) 2810 8185